Kymera Therapeutics, Inc. vs Merck & Company, Inc. — Stock Comparison

KYMR
Kymera Therapeutics, Inc.
$80.71
▼ 0.44%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 5.8/10

Q·Score Breakdown

5.8
Neutral
Overall
6.7
Neutral
1.7
Quality
6.2
8.2
Health
7
6.1
Growth
6.2
6
Valuation
7.2
8.9
Sentiment
7.1
KYMR

96% of 23 covering analysts have a positive rating.

low return on equity (-27%).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $118.86 (+47.3%)
21 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

KYMR
MRK
Trailing P/E
31.5×
-19.9×
Forward P/E
11.5×
0.0%
Profit Margin
13.6%
0.0%
Gross Margin
76.6%
-27.1%
ROE
55.5%
Revenue Growth
4.9%
Earnings Growth
Beta
0.28
Price / Book
$6.6B
Market Cap
$277.0B
$28 – $103
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →